Comparative Pharmacology
Head-to-head clinical analysis: NAGLAZYME versus STRENSIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAGLAZYME versus STRENSIQ.
NAGLAZYME vs STRENSIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NAGLAZYME (galsulfase) is a recombinant form of human N-acetylgalactosamine 4-sulfatase that replaces deficient endogenous enzyme in patients with mucopolysaccharidosis VI (MPS VI). It catalyzes the hydrolysis of N-acetylgalactosamine 4-sulfate groups from glycosaminoglycans (GAGs), reducing GAG accumulation in lysosomes.
Human recombinant tissue-nonspecific alkaline phosphatase (TNSALP) that hydrolyzes inorganic pyrophosphate (PPi), a natural inhibitor of hydroxyapatite crystal growth, thereby promoting bone mineralization.
1 mg/kg intravenously once weekly.
6 mg/kg administered subcutaneously once weekly.
None Documented
None Documented
Terminal elimination half-life: 6-9 minutes (0.1-0.15 hours); clinically, rapid clearance requires weekly intravenous administration to maintain therapeutic levels.
Terminal elimination half-life approximately 5.1 days (123 hours) in adults; supports once-weekly subcutaneous dosing for sustained pharmacodynamic effect.
Renal: 87% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination.
Renal (primarily via proteolytic catabolism into small peptides and amino acids); negligible biliary or fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy